Gut microbiota therapy in gastrointestinal diseases

Area of Science:

• Microbiome research
• Gastroenterology
• Immunology

Background:

• The human gut microbiota comprises trillions of microorganisms essential for gastrointestinal health.
• Microbial imbalances, or dysbiosis, are associated with inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, and colorectal cancer.
• Gut microbiota interactions influence host immunity and the gut-brain axis, affecting disease pathogenesis.

Purpose of the Study:

• To review the role of gut microbiota in common gastrointestinal diseases.
• To explore emerging microbiome-based therapeutic strategies.
• To discuss the scientific basis, clinical effectiveness, and challenges of microbiome interventions.

Main Methods:

• Literature review of studies on gut microbiota and gastrointestinal disorders.
• Analysis of therapeutic approaches including probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary modifications.
• Examination of the scientific evidence and clinical outcomes of microbiome modulation.

Main Results:

• Dysbiosis is a significant factor in the development and progression of various GI disorders.
• Microbiome-targeted therapies demonstrate potential in restoring microbial balance and alleviating disease symptoms.
• Interventions like probiotics, prebiotics, and FMT offer novel treatment avenues.

Conclusions:

• Microbiome-based treatments represent a promising frontier in managing GI disorders.
• These therapies offer personalized and alternative options to conventional treatments.
• Continued research is crucial for optimizing microbiome interventions for improved patient outcomes.